Welcome to our dedicated page for ANTERIS TECHNOLOGIES GLOBAL news (Ticker: AVR), a resource for investors and traders seeking the latest updates and insights on ANTERIS TECHNOLOGIES GLOBAL stock.
Anteris Technologies Global Corp. develops structural heart medical devices for aortic valve disease, with its lead product, the DurAVR® Transcatheter Heart Valve, designed for patients with aortic stenosis. News about AVR commonly centers on the DurAVR THV System, the ADAPT® anti-calcification tissue technology, the ComASUR® Delivery System and the company’s work in transcatheter aortic valve replacement.
Company updates also cover the PARADIGM global pivotal trial, including clinical enrollment, U.S. reimbursement under Medicare coverage for TAVR procedures, regulatory and clinical strategy, manufacturing expansion, capital raises, strategic investment activity, financial results and healthcare investor conference presentations. The company is listed on Nasdaq and ASX under the symbol AVR.
Anteris (NASDAQ: AVR, ASX: AVR) appointed Susan Knight and Stephen Denaro to its Board of Directors. Knight becomes a Class I Director through 2028 and joins the Audit and Risk Committee; Denaro serves as a Class II Director through 2026.
According to Anteris, these appointments support governance as the company advances the DurAVR® PARADIGM pivotal trial and prepares for potential U.S. and EMA licensure for treating aortic stenosis.
Anteris (NASDAQ/ASX: AVR) reported Q1 2026 results and clinical progress. The company completed $320 million in capital raises in January 2026 to fund the PARADIGM pivotal trial and advance DurAVR® THV commercialization.
PARADIGM enrollment continued in Europe and began in the U.S., supported by a CMS TAVR coverage determination. Net operating cash outflows were $28.7 million, including $17.5 million in R&D expenses focused on manufacturing scale-up and trial-related activities. Anteris also presented new DurAVR® clinical data from the EMBARK and U.S. Early Feasibility studies at CRT 2026 and Sydney Valves 2026.
Anteris Technologies (NASDAQ: AVR) announced on May 5, 2026 that the first U.S. patients were enrolled and treated in the global pivotal PARADIGM Trial evaluating the DurAVR® Transcatheter Heart Valve for severe calcific aortic stenosis.
Procedures were performed by Dr. Azeem Latib at Montefiore Medical Center. The trial will assess safety, hemodynamics, and the impact of flow patterns on left ventricular recovery. Company leadership cited rapid U.S. site activation following CMS approval.
Anteris Technologies (NASDAQ: AVR) secured U.S. Medicare reimbursement eligibility for the global pivotal PARADIGM Trial under a Centers for Medicare & Medicaid Services national coverage policy.
Eligible procedures at participating U.S. study sites are covered under the TAVR National Coverage Determination 20.32, using a Coverage with Evidence Development (CED) model to enable reimbursement while generating clinical evidence and support U.S. site activation.
Anteris (NASDAQ: AVR) reported 2025 results and a corporate update, highlighting initiation of the global pivotal PARADIGM Trial, FDA IDE approval in Q4 2025, favorable 30‑day (100 patients) and 1‑year (65 patients) DurAVR clinical outcomes, ISO 13485 progress, and board additions.
Net operating cash outflows were $77.8M; R&D was $69.1M; SG&A was $26.1M. The company completed aggregate capital raises of $320M in early 2026, including a strategic investment from Medtronic.
Anteris (NASDAQ: AVR) announced that CEO Wayne Paterson will present at two investor conferences in March 2026: TD Cowen on March 2, 2026 and Barclays on March 10, 2026. Both appearances include fireside chats and 1x1 meetings with webcasts available.
Webcast links and replays (archived for up to 90 days) are available via the company investor presentations page.
Anteris Technologies (NASDAQ: AVR) announced completion of a $90 million strategic investment from Medtronic, closing immediately after an underwritten common stock offering for a combined $320 million in gross proceeds on Jan 22, 2026. The capital is intended to fund the global pivotal PARADIGM trial and advance commercialization of the DurAVR® Transcatheter Heart Valve (THV). Wells Fargo Securities served as sole placement agent for the Medtronic investment. Management described the funding as validation of the program and said the investment could expand into additional strategic collaboration areas.
Anteris Technologies Global Corp (NASDAQ: AVR) announced the closing of a public offering of 40,000,000 common shares and a private placement of 15,652,173 shares to Medtronic, each at $5.75 per share. Gross proceeds from both transactions were approximately $320 million before fees and expenses. Underwriters included Barclays, Wells Fargo Securities and Cantor; Wells Fargo acted as placement agent for the Medtronic sale. The company said net proceeds will fund the global pivotal PARADIGM Trial for the DurAVR THV, expand manufacturing, support R&D for v2vmedtech, and for working capital and general corporate purposes.
Anteris Technologies Global Corp (NASDAQ: AVR) priced a public offering of 34,782,609 shares at $5.75 per share, generating approximately $200.0 million in gross proceeds, with expected closing on January 22, 2026.
The company granted underwriters a 30-day option to buy an additional 5,217,391 shares. Separately, Anteris agreed to a private placement to Medtronic of up to $90.0 million of shares at the same price, subject to a minimum purchase equal to 16.0% and a maximum of 19.99% of post-offering outstanding shares; the private placement is contingent on the Offering.
Net proceeds are intended to fund the global pivotal PARADIGM Trial for the DurAVR THV, expand manufacturing, support R&D at v2vmedtech, and for working capital.
Anteris Technologies Global Corp (NASDAQ: AVR) announced a proposed public offering of $200.0 million of common stock with a 30-day underwriter option for an additional $30.0 million. Concurrently, Anteris agreed to a private placement with Medtronic for up to $90.0 million of shares at the public offering price, subject to a minimum purchase equal to 16.0% and a maximum of 19.99% of outstanding shares after the Offering. Completion of Medtronic's Private Placement is contingent on completion of the Offering; the Offering is not contingent on the Private Placement.
Proceeds, together with existing cash, are intended to fund the PARADIGM pivotal trial for the DurAVR THV, manufacturing expansion, R&D for v2vmedtech, working capital, and general corporate purposes. Barclays, Wells Fargo Securities and Cantor are joint book-runners; Wells Fargo is placement agent for the private placement.